021-51111890
购物车（）
sales@molnova.cn
Pracinostat
CAS No. 929016-96-6
Pracinostat ( SB939;SB-939;SB 939 )
产品货号. M16653 CAS No. 929016-96-6
Pracinostat (SB939) is a potent, orally active HDAC inhibitor that potently inhibits class I, II, and IV HDACsw with Ki of 15-100 nM, inhibits HDAC1 with IC50 of 77 nM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥502 | 有现货 |
|
| 5MG | ￥794 | 有现货 |
|
| 10MG | ￥1442 | 有现货 |
|
| 25MG | ￥2406 | 有现货 |
|
| 50MG | ￥3637 | 有现货 |
|
| 100MG | ￥5370 | 有现货 |
|
| 500MG | ￥11259 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Pracinostat
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Pracinostat (SB939) is a potent, orally active HDAC inhibitor that potently inhibits class I, II, and IV HDACsw with Ki of 15-100 nM, inhibits HDAC1 with IC50 of 77 nM.
-
产品描述Pracinostat (SB939) is a potent, orally active HDAC inhibitor that potently inhibits class I, II, and IV HDACsw with Ki of 15-100 nM, inhibits HDAC1 with IC50 of 77 nM; shows cellular potency against COLO 205 cells with IC50 of 0.56 uM; Pracinostat (SB939) is highly efficacious in in vivo tumor models (HCT-116, PC-3, A2780, MV4-11, Ramos), and has high and dose-proportional oral exposures and very good ADME, safety, and pharmaceutical properties; also is a potent inhibitor of the growth of Plasmodium falciparum asexual-stage parasites in vitro (IC50=100 to 200 nM), causing hyperacetylation of parasite histone and nonhistone proteins.Blood Cancer Phase 3 Clinical
-
同义词SB939;SB-939;SB 939
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC1;HDAC10;HDAC11;HDAC2;HDAC3;HDAC4;HDAC5;HDAC6;HDAC7;HDAC8;HDAC9
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number929016-96-6
-
分子量358.48
-
分子式C20H30N4O2
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=C(NO)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1
-
化学全称2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Wang H, et al. J Med Chem. 2011 Jul 14;54(13):4694-720.
2. Novotny-Diermayr V, et al. Mol Cancer Ther. 2011 Jul;10(7):1207-17.
3. Sumanadasa SD, et al. Antimicrob Agents Chemother. 2012 Jul;56(7):3849-56.
4. Razak AR, et al. Br J Cancer. 2011 Mar 1;104(5):756-62.
2. Novotny-Diermayr V, et al. Mol Cancer Ther. 2011 Jul;10(7):1207-17.
3. Sumanadasa SD, et al. Antimicrob Agents Chemother. 2012 Jul;56(7):3849-56.
4. Razak AR, et al. Br J Cancer. 2011 Mar 1;104(5):756-62.
产品手册
关联产品
-
CAY-10603
A highly potent and selective HDAC6 inhibitor with IC50 of 2 pM.
-
JAK/HDAC-IN-1
JAK/HDAC-IN-1 is an effective JAK2/HDAC dual inhibitor (IC50s: 4 and 2 nM for JAK2 and HDAC). It also shows antiproliferative and proapoptotic activities in several hematological cell lines.
-
Exifone
Exifone is a mixed, nonessential activator of HDAC1 that is capable of binding to both free and substrate-bound enzyme, resulting in an increased relative maximal rate of HDAC1-catalyzed deacetylation.
